BioSpace News Archive

Evolus, Inc. announced that after nearly four years with the company, Lauren Silvernail will retire from her position as Chief Financial Officer and Executive Vice President of Corporate Development effective May 31, 2022.

KalVista Pharmaceuticals, Inc., announced that the compensation committee of KalVista’s board of directors granted one newly-hired employee inducement options to purchase an aggregate of 5,000 shares of KalVista common stock on March 1, 2022 as inducement material to such employee entering into employment with KalVista.

Evolus, Inc., a performance beauty company with a customer-centric approach focused on delivering breakthrough products, reported financial results for the fourth quarter and full-year ended December 31, 2021 and provided a business update.

BioSyent Inc. will be reporting its financial results for the three months and full year ended December 31, 2021 on Wednesday, March 9, 2022 after market close.

Biognosys announced the launch of its expanded suite of proteomics platforms that provide pharmaceutical and diagnostics customers with deep biological insights across the entire R&D pipeline, from early stage discovery to clinical settings.

The introduction of immune checkpoint inhibitors has greatly revolutionized the overall paradigm of cancer therapy. Immune checkpoint inhibitors have shown encouraging response in the management of several malignancies including melanoma, non-small cell lung cancer, bladder cancer, urothelial cancer, and others.

Immunicom, Inc., a clinical-stage biotechnology company pioneering subtractive therapies for cancer and autoimmune diseases, announced that Dr. Julie Tubbs and Marilyn Panahi have joined the Company’s senior leadership team.

Dynavax Technologies Corporation reported that it has granted restricted stock units covering an aggregate of 16,000 shares of Dynavax common stock as inducements to 2 newly-hired employees in connection with commencement of employment with the Company.

Gossamer Bio, Inc. announced its financial results for the fourth quarter and year ended December 31, 2021 and provided a business update.

Modular Medical Inc., a development stage, insulin delivery technology company seeking to launch the next generation of easy to use and affordable insulin pump technology, announced that the Company will present at Oppenheimer’s 32nd Annual Healthcare Conference.